Antonelli G, Dianzani F
Institute of Virology, University "La Sapienza", V.le di Porta Tiburtina 28 - 00185 Rome, Italy.
Eur Cytokine Netw. 1999 Sep;10(3):413-22.
There are now several papers describing the development of antibodies to interferons (IFN) in patients undergoing IFN therapy. Moreover, there is increasing evidence to indicate that the development of antibodies to IFN may be associated with a failure of the beneficial effects of the therapy. This paper will review and discuss what is currently known about the technical, and biological aspects of antibodies to IFN, with particular reference to antibodies to IFN beta that develop during therapy. Three main considerations arise from the data. Firstly, a standardized quantitative assay to detect antibody to IFN must be agreed upon. Only when results can be compared, both qualitatively and quantitatively, will it be possible to monitor fully the ability of antibodies to cause a relapse during treatment. Secondly, sufficient data are now available to provide a rationale for monitoring the presence of anti-IFN antibodies in patients treated with IFN. This approach may allow a better understanding of the disease reactivation state observed in numerous patients treated with IFN. Finally, approaches aimed at limiting the immunogenicity of IFN preparations and/or strategies designed to circumvent antibody-mediated resistance to IFN treatment are required.
现在有几篇论文描述了接受干扰素（IFN）治疗的患者体内抗干扰素抗体的产生情况。此外，越来越多的证据表明，抗干扰素抗体的产生可能与治疗的有益效果不佳有关。本文将回顾并讨论目前关于抗干扰素抗体的技术和生物学方面的已知情况，特别提及治疗期间产生的抗β-干扰素抗体。从这些数据中产生了三个主要考虑因素。首先，必须商定一种标准化的定量检测方法来检测抗干扰素抗体。只有当结果能够在定性和定量上进行比较时，才有可能充分监测抗体在治疗期间导致复发的能力。其次，现在有足够的数据为监测接受干扰素治疗的患者体内抗干扰素抗体的存在提供理论依据。这种方法可能有助于更好地理解在众多接受干扰素治疗的患者中观察到的疾病再激活状态。最后，需要采取旨在限制干扰素制剂免疫原性的方法和/或设计用来规避抗体介导的对干扰素治疗耐药性的策略。
